Alnara raises $35 million as non-porcine PERT nears NDA filing
This article was originally published in Scrip
Alnara Pharmaceuticals has raised $35 million in a series B financing round. The proceeds will be used to advance its lead programme liprotamase, an oral non-porcine recombinant-derived pancreatic enzyme replacement therapy (PERT) which has completed Phase III development in collaboration with the Cystic Fibrosis Foundation. The US company expects to file the NDA with the US FDA in the first quarter.
You may also be interested in...
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.